MedTrace Logo

Buprenorphine Treatment Engagement and Overdose Prevention

NCT03677986 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2024-02-20

Study results available
· View outcomes & findings →

Summary

Office-based buprenorphine could be expanded to treat many of the opioid users who are not in treatment and who are at great risk for opioid overdose, but effective approaches are needed to help individuals with opioid use disorder initiate and remain in office-based buprenorphine treatment. Investigators propose to develop and pilot test a novel intervention that will combine video-based directly observed therapy and incentives to promote buprenorphine treatment engagement and adherence in out-of-treatment opioid users.

Conditions

  • Opioid-use Disorder

Interventions

BEHAVIORAL

Video DOT+

Participants will receive financial incentives for recording and submitting videos of themselves taking their daily buprenorphine dose.

Sponsors & Collaborators

Principal Investigators

  • Kenneth Silverman, Ph.D. · Johns Hopkins School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-07-28
Completion
2020-10-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03677986 on ClinicalTrials.gov